TD Cowen Downgrades Novo Nordisk on Semaglutide Patent and Pipeline Concerns
TD Cowen has downgraded Novo Nordisk A/S (NVO) from Buy to Hold, setting a price target of $42 per share. The downgrade centers on growing concerns about the company’s ability to sustain its competitive position as its blockbuster drug semaglutide — the active ingredient in Ozempic and Wegovy — approaches loss of exclusivity (LOE). Despite the downgrade, the $42 price target still implies roughly 6% upside from recent trading levels.
Why the Rating Changed
The core of TD Cowen’s thesis is straightforward: Novo Nordisk faces what the firm describes as “enormous challenges” ahead of semaglutide’s loss of exclusivity. More critically, the analyst team concluded that the company’s pipeline is “not poised to blunt semaglutide LOE,” meaning Novo Nordisk may not have a next-generation product portfolio strong enough to offset the eventual revenue decline when generic and biosimilar competition arrives for semaglutide.
Semaglutide is the foundation of Novo Nordisk’s GLP-1 franchise, which has driven exceptional revenue growth in recent years across both diabetes and obesity indications. A loss of exclusivity would open the door for competitors and compounding pharmacies to erode market share and pricing power — a significant headwind for a company whose valuation is closely tied to GLP-1 dominance.
Several additional factors appear to be weighing on the outlook for Novo Nordisk:
- FDA Warning Letter: Novo Nordisk recently acknowledged receipt of a warning letter from the U.S. FDA related to a post-marketing adverse drug experience inspection conducted at its Plainsboro, New Jersey site in early 2025. While the company stated it does not expect the letter to impact production or its full-year guidance, it adds a layer of regulatory scrutiny at a sensitive time.
- Competitive Pressures in GLP-1 Market: Recent news highlights a renewed GLP-1 deal between Novo Nordisk and Hims & Hers Health, which sent Hims & Hers shares surging 40%. While partnerships like these can expand volume, they also raise questions about pricing dynamics and the evolving competitive landscape in the GLP-1 space.
- Pipeline Uncertainty: TD Cowen’s concern is not merely about patent expiration timing but about whether Novo Nordisk’s development-stage assets can generate enough commercial momentum to replace semaglutide revenues. The firm’s assessment suggests the current pipeline falls short of that threshold.
Novo Nordisk’s Dividend Profile
For income-focused investors, Novo Nordisk currently pays an annual dividend of $1.86 per share, which translates to a dividend yield of approximately 4.67%. The most recent ex-dividend date was March 29, 2026. This yield is notably higher than the company’s historical average, reflecting the significant decline in share price over recent quarters. While the yield may appear attractive, dividend investors should weigh the sustainability of payouts against the longer-term revenue risks highlighted by TD Cowen’s downgrade, particularly as semaglutide LOE approaches and pipeline replacement products remain uncertain.
What This Means for Investors
TD Cowen’s move from Buy to Hold reflects a shift from optimism to caution. The firm still sees modest upside to its $42 price target, but the risk-reward profile has changed. The central question for Novo Nordisk investors going forward is whether the company can develop or acquire pipeline assets capable of sustaining growth beyond semaglutide’s period of market exclusivity. Until there is greater clarity on that front, TD Cowen appears content to stand on the sidelines.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.